RecruitingPhase 1Phase 2NCT05130437

A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study

A Phase 1/2, Global, Open-Label, Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study


Sponsor

ModernaTX, Inc.

Enrollment

50 participants

Start Date

Nov 9, 2021

Study Type

INTERVENTIONAL

Conditions

Summary

The main purpose of this study is to evaluate the long-term safety of mRNA-3927 administered to participants with propionic acidemia (PA) who have previously participated in Study mRNA-3927-P101 (NCT04159103).


Eligibility

Min Age: 1 Year

Inclusion Criteria2

  • Participated in Study mRNA-3927-P101.
  • Completed the EOT/ET visit in Study mRNA-3927-P101 and enroll in this study such that the first dose in this study is planned to be within 14±3 days of the last dose of mRNA-3927 in the mRNA-3927-P101 study.

Exclusion Criteria3

  • Not expected to receive clinical benefit from continued mRNA-3927 administration, in the opinion of the Investigator.
  • Any clinical or laboratory abnormality or medical condition that, at the discretion of the Investigator, may put the individual at increased risk by participating in this study.
  • History of liver and/or kidney transplant.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALmRNA-3927

mRNA-3927 dispersion for IV infusion


Locations(22)

Ronald Reagan UCLA Medical Center

Los Angeles, California, United States

University of Stanford Medical Center

Palo Alto, California, United States

University of Michigan Hospitals

Ann Arbor, Michigan, United States

Icahn School of Medicine at Mount Sinai

New York, New York, United States

Duke University Medical System (Duke Health)

Durham, North Carolina, United States

The Children's Hospital of Philadelphia (CHOP)

Philadelphia, Pennsylvania, United States

Texas Children's Hospital

Houston, Texas, United States

Hospital For Sick Children

Toronto, Ontario, Canada

AP-HM- Hôpital de La Timone

Marseille, France

Hôpital Necker - Enfants Malades

Paris, France

Fujita Health University Hospital

Toyoake-shi, Akita, Japan

Tohoku University Hospital

Sendai, Miyagi, Japan

Erasmus MC -Dr. Molewaterplein 40

Rotterdam, South Holland, Netherlands

Universitair Medisch Centrum Utrecht - PPDS

Utrecht, Netherlands

King Faisal Specialist Hospital & Research Centre

Riyadh, Ar Riya, Saudi Arabia

King Abdullah Children's Specialist Hospital

Riyadh, Ar Riya, Saudi Arabia

Hospital Universitario Cruces

Barakaldo, Vizcaya, Spain

Hospital Universitario 12 de Octubre

Madrid, Spain

Willink Biochemical Genetics Unit - Manchester

Manchester, England, United Kingdom

University Hospital Birmingham NHS Foundation Trust

Birmingham, West Midlands, United Kingdom

Birmingham Women's and Children's NHS Foundation Trust

Birmingham, West Midlands, United Kingdom

Great Ormond Street Hospital for Children NHS Foundation Trust

London, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05130437


Related Trials